Mydecine Innovations Group (OTCMKTS:MYCOF) Trading Down 0.3% – Time to Sell?

Mydecine Innovations Group Inc. (OTCMKTS:MYCOF)’s share price was down 0.3% on Friday . The company traded as low as $1.0763 and last traded at $1.0763. Approximately 672 shares were traded during mid-day trading, a decline of 84% from the average daily volume of 4,247 shares. The stock had previously closed at $1.08.

Mydecine Innovations Group Stock Down 0.3%

The stock has a 50 day moving average of $1.13 and a two-hundred day moving average of $0.48.

About Mydecine Innovations Group

Mydecine Innovations Group (OTCMKTS:MYCOF) is a clinical‐stage biotechnology company dedicated to the research, development and commercialization of novel therapeutics derived from psychedelic and plant-based compounds. The company’s primary focus lies in advancing a pipeline of next‐generation product candidates targeting mental health disorders, addiction and other neurological conditions. Mydecine holds a portfolio of intellectual property that encompasses proprietary chemical entities, drug delivery systems and manufacturing processes for molecules such as 5-MeO-DMT analogs, ibogaine-derived compounds and psilocybin formulations.

Headquartered in Denver, Colorado, with additional research and manufacturing facilities in Vancouver, Canada, Mydecine operates a vertically integrated business model.